Preliminary results of a Phase I clinical trial showed 85 percent of patients who received high dosages of Princeton, N.J.-based Pharmasset Inc.'s R7128 in combination with Pegasys (pegylated interferon) and Copegus (ribavirin) achieved undetectable levels of hepatitis C virus (HCV) after four weeks of treatment News of the results sent shares of Pharmasset (NASDAQ:VRUS) up 44.7 percent Jan. 7, or $6.25, to close at $20.24. The combination trial evaluated R7128 in 50 patients with HCV genotype-1 who …
No comments:
Post a Comment